This CDC MMWR summarizes the clinical and epidemiologic characteristics of people with a severe allergic reaction known as anaphylaxis who received the first dose of Moderna COVID-19 vaccine in the United States during the first three weeks of vaccine administration. Early safety monitoring of the Moderna COVID-19 vaccine detected 10 people with anaphylaxis among more than 4 million first doses of Moderna COVID-19 vaccine that were administered. Among those with follow-up information available, all recovered or were discharged home.
More NACCHO Blogs
The Word on Local Health Departments is a blog by the National Association of County and City Health Officials (NACCHO).
The Preparedness Brief provides updates and information from NACCHO’s public health preparedness portfolio.